Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease

The baseline imaging characteristics of the DIAN-TU-001 trial population reveal significant spatial differences in tau PET and vMRI between symptomatic and asymptomatic DIAD subjects. Baseline amyloid levels were consistent with the stage of disease in DIAD. Symptomatic DIAD subjects exhibit higher tau SUVR values and greater atrophy, particularly in the parietal cortex, compared to asymptomatic DIAD subjects. These tau PET findings corroborate the distinctly different pattern of tau deposition in DIAD vs. sporadic AD, as previously reported. Future analysis will elucidate the therapeutic effects of E2814 and lecanemab on this pathological tau spread.